Imagine a drug, used for 70 years to save mothers from deadly high blood pressure, that might also hold the key to stopping brain cancer. That's the astonishing possibility researchers are exploring with hydralazine, a long-standing medication that's been a crucial tool, especially in treating preeclampsia during pregnancy. But here's the kicker: for decades, scientists didn't fully understand how it worked!
This mystery has finally been cracked, potentially opening doors to new treatments for both maternal health and a devastating form of brain cancer called glioblastoma.
Dr. Kyosuke Shishikura, a physician-scientist at the University of Pennsylvania, explains, "Hydralazine is one of the oldest vasodilators we have, and it remains a primary treatment for preeclampsia, a condition affecting 5-15% of pregnancies and significantly contributing to maternal mortality worldwide." He points out that hydralazine was developed in a "pre-target" era, meaning doctors saw it worked in patients and then tried to figure out the underlying biology.
Now, Dr. Shishikura, alongside his postdoctoral advisor Megan Matthews and a team of collaborators, has published groundbreaking research in Science Advances that unravels hydralazine's mechanism of action and, surprisingly, links high blood pressure disorders to brain cancer. This discovery showcases how older, well-established drugs can reveal unexpected therapeutic benefits.
Megan Matthews emphasizes the personal significance of this research: "Preeclampsia has impacted generations of women in my family and continues to disproportionately affect Black mothers in the United States." She adds that by understanding hydralazine's molecular workings, we can pave the way for safer, more targeted treatments for pregnancy-related hypertension, potentially improving outcomes for those most at risk. And this is the part most people miss: it's not just about treating a symptom; it's about understanding the root cause to create truly effective solutions.
So, how does hydralazine work? The team discovered that it blocks an enzyme called 2-aminoethanethiol dioxygenase (ADO), which acts as an oxygen sensor. Matthews describes ADO as an "alarm bell that rings when oxygen levels start to drop." Most bodily processes are slow and complex, involving DNA, RNA, and protein synthesis. But ADO is incredibly fast, flipping a biochemical switch in mere seconds. Hydralazine essentially "mutes" this alarm by binding to and blocking ADO. When ADO is silenced, signaling proteins called regulators of G-protein signaling (RGS) remain stable.
Dr. Shishikura explains that the accumulation of RGS proteins signals blood vessels to relax, effectively overriding the constriction signal. This leads to reduced intracellular calcium levels, the "master regulator of vascular tension." As calcium decreases, the smooth muscles in blood vessel walls relax, causing vasodilation and a drop in blood pressure.
But here's where it gets controversial... Could a drug primarily designed for blood pressure offer a new weapon against brain cancer?
Before this study, cancer researchers suspected ADO's role in glioblastoma, where tumors often survive in low-oxygen environments. Elevated ADO levels were linked to more aggressive disease, suggesting that inhibiting this enzyme could be beneficial. However, a good inhibitor wasn't available – until now.
To investigate hydralazine's potential, Dr. Shishikura collaborated with structural biochemists at the University of Texas, who used X-ray crystallography to visualize hydralazine bound to ADO. He also worked with neuroscientists at the University of Florida to test the drug's effects on brain cancer cells.
The results were promising. The ADO pathway, which regulates vascular contraction, also helps tumor cells survive in low-oxygen conditions. Unlike chemotherapy, which aims to kill all cells, hydralazine disrupted the oxygen-sensing loop, triggering cellular senescence – a dormant, non-dividing state – in glioblastoma cells. This effectively paused tumor growth without causing further inflammation or resistance.
The implications are huge. The findings demonstrate how established treatments can uncover new therapeutic avenues and aid in designing safer, more effective drugs for both maternal health and brain cancer. The next step, according to the researchers, is to develop new ADO inhibitors that are more tissue-specific and can better cross the blood-brain barrier, targeting tumor tissue more effectively while minimizing side effects.
Matthews is dedicated to continuing to reveal the mechanics of clinically tested treatments to engineer the next generation of medical solutions.
"It's rare for an old cardiovascular drug to teach us something new about the brain," Matthews concludes, "but that's exactly what we're hoping to find more of – unusual links that could lead to new solutions."
This research raises exciting possibilities, but also important questions. Could hydralazine, or similar drugs, become a standard part of glioblastoma treatment? What are the potential long-term effects of blocking ADO in different tissues? And this is a question for you: What other seemingly unrelated drugs might hold hidden potential for treating different diseases? Share your thoughts and ideas in the comments below!
